199 related articles for article (PubMed ID: 16705719)
1. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.
Arabmotlagh M; Rittmeister M; Hennigs T
J Orthop Res; 2006 Jul; 24(7):1336-41. PubMed ID: 16705719
[TBL] [Abstract][Full Text] [Related]
2. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients.
Tapaninen TS; Venesmaa PK; Jurvelin JS; Miettinen HJ; Kröger HP
Scand J Surg; 2010; 99(1):32-7. PubMed ID: 20501356
[TBL] [Abstract][Full Text] [Related]
3. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.
Arabmotlagh M; Pilz M; Warzecha J; Rauschmann M
J Orthop Res; 2009 Feb; 27(2):183-8. PubMed ID: 18752281
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
[TBL] [Abstract][Full Text] [Related]
6. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
[TBL] [Abstract][Full Text] [Related]
7. [Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study].
Nehme A; Maalouf G; Tricoire JL; Giordano G; Chiron P; Puget J
Rev Chir Orthop Reparatrice Appar Mot; 2003 Nov; 89(7):593-8. PubMed ID: 14699304
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
Yukizawa Y; Inaba Y; Kobayashi N; Choe H; Kubota S; Saito T
J Arthroplasty; 2017 Jul; 32(7):2176-2180. PubMed ID: 28318867
[TBL] [Abstract][Full Text] [Related]
9. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study.
Venesmaa PK; Kröger HP; Miettinen HJ; Jurvelin JS; Suomalainen OT; Alhav EM
J Bone Miner Res; 2001 Nov; 16(11):2126-31. PubMed ID: 11697810
[TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis.
Zhao X; Hu D; Qin J; Mohanan R; Chen L
J Orthop Surg Res; 2015 May; 10():65. PubMed ID: 25962791
[TBL] [Abstract][Full Text] [Related]
11. No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial.
Muren O; Akbarian E; Salemyr M; Bodén H; Eisler T; Stark A; Sköldenberg O
Acta Orthop; 2015; 86(5):569-74. PubMed ID: 25885280
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
[TBL] [Abstract][Full Text] [Related]
14. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
15. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
16. Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial.
Morita A; Kobayashi N; Choe H; Ike H; Tezuka T; Higashihira S; Inaba Y
J Orthop Surg Res; 2020 Jan; 15(1):17. PubMed ID: 31948455
[TBL] [Abstract][Full Text] [Related]
17. Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty.
Nagoya S; Tateda K; Okazaki S; Kosukegawa I; Shimizu J; Yamashita T
Eur J Orthop Surg Traumatol; 2018 Dec; 28(8):1601-1607. PubMed ID: 29774416
[TBL] [Abstract][Full Text] [Related]
18. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
Greenspan SL; Resnick NM; Parker RA
J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
[TBL] [Abstract][Full Text] [Related]
19. Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial.
Fokter SK; Komadina R; Repse-Fokter A
Wien Klin Wochenschr; 2006; 118 Suppl 2():23-8. PubMed ID: 16817039
[TBL] [Abstract][Full Text] [Related]
20. Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss.
Ji WP; Wang XL; Ma MQ; Lan J; Li H
Eur J Orthop Surg Traumatol; 2013 Jul; 23(5):565-71. PubMed ID: 23412167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
